COVID-19疫苗接种后眼部炎症事件:英国监管机构疑似药物不良反应报告
分析英国MHRA在2021年1月至2022年9月间收集的COVID-19疫苗接种后疑似眼部炎症事件的自发报告,共300例,计算患病率为每100万接种者6.6例。前葡萄膜炎最常见(58.3%),其次为视神经炎(39.3%),接种至发病中位时间8天,52.3%事件缓解。结论认为英国此类事件患病率极低,且葡萄膜炎、视神经炎和巩膜炎的报告率与英国人群发病率范围相比未见增加。
要点
- MHRA收到300例COVID-19疫苗接种后疑似眼部炎症事件报告,患病率为每100万接种者6.6例。
- 前葡萄膜炎最常见(58.3%),其次为视神经炎(39.3%)。
- 接种至发病中位时间8天,52.3%事件缓解。
核心结论
- COVID-19疫苗接种后眼部炎症事件在英国患病率极低。
- 与英国人群发病率范围相比,COVID-19疫苗接种后葡萄膜炎、视神经炎和巩膜炎的报告率未见增加。
- 黄卡系统是药物警戒领域的重要工具,使患者和医疗专业人员能够参与药物安全性的持续监测。
研究设计与样本
- 分析英国药品和保健品监管局(MHRA)收集的2021年1月至2022年9月期间COVID-19疫苗接种后疑似眼部炎症事件的自发报告数据。
主要发现
- MHRA收到300例英国COVID-19疫苗接种后疑似眼部炎症事件的自发报告,计算患病率为每100万接种者6.6例。
- 前葡萄膜炎是最常见的表型(58.3%),其次为视神经炎(39.3%)。
- 接种至发病的中位天数为8天。
- 52.3%的事件缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: The UK Medicines and Healthcare products Regulatory Agency (MHRA) has published suspected adverse drug reactions to vaccines against COVID-19. Ocular inflammatory events following COVID-19 vaccination have been reported worldwide. METHODS: We analysed MHRA data on spontaneous reports of suspected ocular inflammatory events following COVID-19 vaccination between January 2021 and September 2022. RESULTS: The MHRA received 300 UK spontaneous suspected reports of ocular inflammatory events following COVID-19 vaccination, with a calculated prevalence of 6.6 events per 1 000 000 vaccinated individuals. Anterior uveitis was the most common phenotype (58.3%), followed by optic neuritis in 39.3%. Median number of days between vaccination and onset was 8 days. Resolution of the event was seen in 52.3%. CONCLUSION: Ocular inflammatory events following COVID-19 vaccination have a very rare prevalence in the UK. There is no increase in the reporting rate of uveitis, optic neuritis and scleritis following COVID-19 vaccination when compared with the range of incidence in the UK population. The Yellow Card System represents a vital instrument within the domain of pharmacovigilance, empowering patients and healthcare professionals to contribute to the ongoing monitoring of medication safety.
引用
- Testi I, Soomro T, Pavesio C, et al. Ocular inflammatory events following COVID-19 vaccination: reporting of suspected adverse drug reactions to regulatory authorities in the UK. Br J Ophthalmol. 2024. PMID: 38041661. doi:10.1136/bjo-2023-324503
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。